Clinical Trial Update: Phase I/II Trial of Sorafenib Plus Ixabepilone in HER2-Negative Metastatic Breast Cancer [Phase 1, Phase 2]

View source ↗

Summary

Phase I/II clinical trial evaluating the combination of sorafenib and ixabepilone in HER2-negative metastatic breast cancer has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Ixempra (ixabepilone)
• Nexavar (Sorafenib)

Snippet

Sponsor: SCRI Development Innovations, LLC | Conditions: Metastatic Breast Cancer | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2014-12-22